Extended Data Fig. 9: Combined MAT2A and GSK3 inhibition limits liver tumor growth.
a, Representative crystal violet staining of Huh7 cells treated with indicated doses of drug combination for 12 days. b-d, Quantification of end point Huh7 and Hep3B xenograft tumor weight (b), volume (c) and mouse body weight (d) from vehicle control (Veh), FIDAS-5, LY2090314 and combined FIDAS-5/LY2090314 treatment groups. Huh7: n = 6 female BAB/c mice for each group. Hep3B: n = 5 female NSG mice for Veh, n = 6 female NSG mice for FIDAS-5, n = 6 female NSG mice for LY2090314, n = 7 female NSG mice for combination group. e, f, Representative IHC images (e) and quantification (f) of PCNA and γH2AX staining in Hep3B xenograft tumor sections from indicated treatment groups. To quantify, 3–5 representative images with a ×200 field of view (FOV) were used for quantification using Image J and averaged for each animal. n = 6 mice for each group. Scale bar: 100 µm. g, Body weight change of vehicle control (n = 3 male mice) and combined FIDAS-5/LY2090314 (n = 3 male mice)-treated C57BL/6 J mice. h, Representative HE staining of liver sections from vehicle and combined FIDAS-5/LY2090314-treated wild type mice. Scale bar: 100 µm. Data presented as mean ± s.e.m. (b-g); statistical significance was determined by a two-tailed Student’s t-test (b-f) Experiments were repeated three times independently, with similar results (a).
